In France, venous thromboembolic (VTE) disease is usually managed by vascular medicine physicians (VMP). The national OPTIMEV study, conducted more than 12 years ago among VMP practicing in hospital and in the community described the management of VTE in routine clinical practice. Since then a large number of practice changing studies have been published. This includes trials that have validated the use of direct oral anticoagulants (DOAC), the new standard of care of VTE, as per new national and international guidelines. Management of VTE in 2019 appears to be significantly different from the one that prevailed more than 10 years ago when the last national survey was conducted. It is therefore important to have an update on the routine clinical practice management of VTE by VMP. In this perspective the investigators aim to conduct a national survey among VMP practicing in France
Study Type
OBSERVATIONAL
Enrollment
383
CHU Amiens
Amiens, France
Inter-practician variability of clinical care of venous thromboembolic in routine clinical practice
The variation in venous thromboembolic management in routine clinical practice is assessed by analysing the management of the 5 consecutive acute venous thromboembolic patients reported by each participating physician
Time frame: up to 3 months after inclusion
Inter-practician variability of clinical care of venous thromboembolic according to patient age
patient characteristics are : cancer, extreme body weight, severe renal impairment, elderly or pregnant patients, high bleeding risk
Time frame: up to 6 months after inclusion
Inter-practician variability of clinical care of venous thromboembolic according to patient body weight
patient characteristics are : cancer, extreme body weight, severe renal impairment, elderly or pregnant patients, high bleeding risk
Time frame: up to 6 months after inclusion
Inter-practician variability of clinical care of venous thromboembolic according to patient bleeding risk
patient characteristics are : cancer, extreme body weight, severe renal impairment, elderly or pregnant patients, high bleeding risk
Time frame: up to 6 months after inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.